ATHE - Alterity Therapeutics to implement 1-for-10 reverse ADS split

• Biotechnology company Alterity Therapeutics ( NASDAQ: ATHE ) is set to implement a 1-for-10 reverse ADS split.
• The board approved a ratio change of its ADSs to ordinary shares from the current ADS ratio of 1 ADS representing 60 ordinary shares to 1 ADS representing 600 ordinary shares.
• The ADS ratio change will be effective on January 9, 2023.
• The move is intended to help regain compliance with Nasdaq's minimum bid price of $1.00 per share. The company has until February 23, 2023 to regain compliance.

For further details see: